Skip to main content
SpringerLink
Log in

Myocardial Regeneration

Present and Future Trends

  • Leading Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Cardiomyocytes are terminally differentiated and are unable to proliferate in response to injury. Genetic modulation, cell transplantation and tissue engineering promise a revolutionary approach for myocardial regeneration and tissue repair after myocardial injury. Current data derived from animal models suggest that it may be possible to treat heart failure by inserting genetic materials or myogenic cells into injured myocardium. Success with animal models has raised the hope for new treatment after heart attacks and could prove an alternative to transplantation, particularly in elderly patients for whom there is often a lack of donor hearts. This exciting research, however, still faces significant difficulties before it can develop into a clinical therapeutic tool and many challenges need to be overcome before cell transplantation, gene therapy and tissue engineering can be considered efficient, therapeutic strategies for myocardial regeneration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sharpe N, Doughty R. Epidemiology of heart failure and ventricular dysfunction. Lancet 1998; 352 Suppl. 1: SI3–7

    Article  PubMed  Google Scholar 

  2. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J 1997; 133: 703–12

    Article  PubMed  CAS  Google Scholar 

  3. Hoes AW, Mosterd A, Grobbee DE. An epidemic of heart failure? Recent evidence from Europe. Eur Heart J 1998; 19 Suppl. L: L2–9

    PubMed  Google Scholar 

  4. Cleland JG, Khand A, Clark A. The heart failure epidemic: exactly how big is it?. Eur Heart J 2001; 22: 623–6

    Article  PubMed  CAS  Google Scholar 

  5. Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J 1999; 20: 136–9

    Article  PubMed  CAS  Google Scholar 

  6. Mann DL. Mechanisms and models in heart failure: A combinatorial approach. Circulation 1999; 100: 999–1008

    Article  PubMed  CAS  Google Scholar 

  7. Reinlib L, Field L. Cell transplantation as future therapy for cardiovascular disease?: A workshop of the National Heart, Lung, and Blood Institute. Circulation 2000; 101: E182–7

    Article  PubMed  CAS  Google Scholar 

  8. Kessler PD, Byrne BJ. Myoblast cell grafting into heart muscle: cellular biology and potential applications. Annu Rev Physiol 1999; 61: 219–42

    Article  PubMed  CAS  Google Scholar 

  9. Soonpaa MH, Koh GY, Klug MG, et al. Formation of nascent intercalated disks between grafted fetal cardiomyocytes and host myocardium [see comments]. Science 1994; 264: 98–101

    Article  PubMed  CAS  Google Scholar 

  10. Koh GY, Kim SJ, Klug MG, et al. Targeted expression of transforming growth factor-beta 1 in intracardiac grafts promotes vascular endothelial cell DNA synthesis. J Clin Invest 1995; 95: 114–21

    Article  PubMed  CAS  Google Scholar 

  11. Leor J, Patterson M, Quinones MJ, et al. Transplantation of fetal myocardial tissue into the infarcted myocardium of rat. A potential method for repair of infarcted myocardium?. Circulation 1996; 94: II332–6

    PubMed  CAS  Google Scholar 

  12. Li RK, Jia ZQ, Weisel RD, et al. Cardiomyocyte transplantation improves heart function. Ann Thorac Surg 1996; 62: 654–60; discussion 660–1

    Article  PubMed  CAS  Google Scholar 

  13. Li RK, Mickle DA, Weisel RD, et al. Natural history of fetal rat cardiomyocytes transplanted into adult rat myocardial scar tissue. Circulation 1997; 96: II-179-86; discussion 186-7

  14. Li RK, Mickle DA, Weisel RD, et al. In vivo survival and function of transplanted rat cardiomyocytes. Circ Res 1996; 78: 283–8

    Article  PubMed  CAS  Google Scholar 

  15. Scorsin M, Hagege AA, Dolizy I, et al. Can cellular transplantation improve function in doxorubicin-induced heart failure?. Circulation 1998; 98: II151–5; discussion II155-6

    PubMed  CAS  Google Scholar 

  16. Scorsin M, Hagege AA, Marotte F, et al. Does transplantation of cardiomyocytes improve function of infarcted myocardium?. Circulation 1997; 96: II188–93

    Google Scholar 

  17. Scorsin M, Marotte F, Sabri A, et al. Can grafted cardiomyocytes colonize peri-infarct myocardial areas?. Circulation 1996; 94: II337–40

    PubMed  CAS  Google Scholar 

  18. Reinecke H, Zhang M, Bartosek T, et al. Survival, integration, and differentiation of cardiomyocyte grafts: A study in normal and injured rat hearts. Circulation 1999; 100: 193–202

    Article  PubMed  CAS  Google Scholar 

  19. Etzion S, Battler A, Barbash IM, et al. Influence of embryonic cardiomyocyte transplantation on the progression of heart failure in a rat model of extensive myocardial infarction. J Mol Cell Cardiol 2001; 33: 1321–30

    Article  PubMed  CAS  Google Scholar 

  20. Yoo KJ, Li RK, Weisel RD, et al. Heart cell transplantation improves heart function in dilated cardiomyopathic hamsters. Circulation 2000; 102: III204–9

    Article  PubMed  CAS  Google Scholar 

  21. Muller-Ehmsen J, Dow JS, Sakoda T, et al. Quantitative analysis of the survival of neonatal cardiomyocytes after grafting into healthy rat left ventricle using fluorescence based real-time TaqMan PCR [abstract]. Circulation 2000; 102 Suppl.: II–651

    Google Scholar 

  22. Zhang M, Methot D, Fujio Y, et al. Cardiomyocyte grafting for cardiac repair: Graft cell death and anti-death strategies. J Mol Cell Cardiol 2001; 33: 907–21

    Article  PubMed  CAS  Google Scholar 

  23. Varda-Bloom N, Leor J, Ohad DG, et al. Cytotoxic T lymphocytes are activated following myocardial infarction and can recognize and kill healthy myocytes in vitro. J Mol Cell Cardiol 2000; 32: 2141–9

    Article  PubMed  CAS  Google Scholar 

  24. Hosenpud JD, Bennett LE, Keck BM, et al. The Registry of the International Society for Heart and Lung Transplantation: sixteenth official report 1999. J Heart Lung Transplant 1999; 18: 611–26

    Article  PubMed  CAS  Google Scholar 

  25. Hooper TL, Stephenson LW. Cardiomyoplasty for end-stage heart failure. Surg Annu 1993; 25: 157–73

    PubMed  Google Scholar 

  26. Chiu RC. Cardiac cell transplantation: the autologous skeletal myoblast implantation for myocardial regeneration. Adv Card Surg 1999; 11: 69–98

    PubMed  CAS  Google Scholar 

  27. Murry CE, Wiseman RW, Schwartz SM, et al. Skeletal myoblast transplantation for repair of myocardial necrosis. J Clin Invest 1996; 98: 2512–3

    Article  PubMed  CAS  Google Scholar 

  28. Pouzet B, Vilquin JT, Hagege AA, et al. Intramyocardial transplantation of autologous myoblasts: can tissue processing be optimized?. Circulation 2000; 102: III210–5

    Article  PubMed  CAS  Google Scholar 

  29. Dorfman J, Duong M, Zibaitis A, et al. Myocardial tissue engineering with autologous myoblast implantation. J Thorac Cardiovasc Surg 1998; 116: 744–51

    Article  PubMed  CAS  Google Scholar 

  30. Taylor DA, Atkins BZ, Hungspreugs P, et al. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation [published erratum appears in Nat Med 1998 Oct; 4 (10): 1200]. Nat Med 1998; 4: 929–33

    Article  PubMed  CAS  Google Scholar 

  31. Scorsin M, Hagege A, Vilquin JT, et al. Comparison of the effects of fetal cardiomyocyte and skeletal myoblast transplantation on postinfarction left ventricular function. J Thorac Cardiovasc Surg 2000; 119: 1169–75

    Article  PubMed  CAS  Google Scholar 

  32. Menasche P, Hagege AA, Scorsin M, et al. Myoblast transplantation for heart failure. Lancet 2001; 357: 279–80

    Article  PubMed  CAS  Google Scholar 

  33. Reinecke H, MacDonald GH, Hauschka SD, et al. Electromechanical coupling between skeletal and cardiac muscle. Implications for infarct repair. J Cell Biol 2000; 149: 731–40

    Article  PubMed  CAS  Google Scholar 

  34. Reinecke H, Murry CE. Transmural replacement of myocardium after skeletal myoblast grafting into the heart. Too much of a good thing?. Cardiovasc Pathol 2000; 9: 337–44

    Article  PubMed  CAS  Google Scholar 

  35. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts [see comments] [published erratum appears in Science 1998 Dec 4; 282 (5395): 1827]. Science 1998; 282: 1145–7

    Article  PubMed  CAS  Google Scholar 

  36. Kahat I, Kenyagin-Karsenti D, Druckmann M, et al. Human embryonic stem cells can differentiate into myocytes portraying cardiomycytic structural and functional properties. J Clin Invest. In press

  37. Shamblott MJ, Axelman J, Littlefield JW, et al. Human embryonic germ cell derivatives express a broad range of developmentally distinct markers and proliferate extensively in vitro. Proc Natl Acad Sci USA 2001; 98: 113–8

    Article  PubMed  CAS  Google Scholar 

  38. Bianco P, Gehron Robey P. Marrow stromal stem cells. J Clin Invest 2000; 105: 1663–8

    Article  PubMed  CAS  Google Scholar 

  39. Wakitani S, Saito T, Caplan AI. Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle Nerve 1995; 18: 1417–26

    Article  PubMed  CAS  Google Scholar 

  40. Makino S, Fukuda K, Miyoshi S, et al. Cardiomyocytes can be generated from marrow stremai cells in vitro. J Clin Invest 1999; 103: 697–705

    Article  PubMed  CAS  Google Scholar 

  41. Shamblott MJ, Axelman J, Wang S, et al. Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc Natl Acad Sci USA 1998; 95: 13726–31

    Article  PubMed  CAS  Google Scholar 

  42. Klug MG, Soonpaa MH, Koh GY, et al. Genetically selected cardiomyocytes from differentiating embronic stem cells form stable intracardiac grafts. J Clin Invest 1996; 98: 216–4

    Article  PubMed  CAS  Google Scholar 

  43. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143–7

    Article  PubMed  CAS  Google Scholar 

  44. Liechty KW, MacKenzie TC, Shaaban AF, et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 2000; 6: 1282–6

    Article  PubMed  CAS  Google Scholar 

  45. Cossu G, Mavilio F. Myogenic stem cells for the therapy of primary myopathies: wishful thinking or therapeutic perspective?. J Clin Invest 2000; 105: 1669–74

    Article  PubMed  CAS  Google Scholar 

  46. Wang JS, Shum-Tim D, Galipeau J, et al. Marrow stremai cells for cellular cardiomyoplasty: feasibility and potential clinical advantages. J Thorac Cardiovasc Surg 2000; 120: 999–1005

    Article  PubMed  CAS  Google Scholar 

  47. Tornita S, Li RK, Weisel RD, et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 1999; 100: II247–56

    Google Scholar 

  48. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410: 701–5

    Article  PubMed  CAS  Google Scholar 

  49. Sussman M. Cardiovascular biologyHearts and bones. Nature 2001; 410: 640–1

    Article  PubMed  CAS  Google Scholar 

  50. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964–7

    Article  PubMed  CAS  Google Scholar 

  51. Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999; 5: 434–8

    Article  PubMed  CAS  Google Scholar 

  52. Shintani S, Murohara T, Ikeda H, et al. Augmentation of postnatal neovascularization with autologous bone marrow transplantation. Circulation 2001; 103: 897–903

    Article  PubMed  CAS  Google Scholar 

  53. Kawamoto A, Gwon HC, Iwaguro H, et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 2001; 103: 634–7

    Article  PubMed  CAS  Google Scholar 

  54. Kocher AA, Schuster MD, Szabolcs MJ, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001; 7: 430–6

    Article  PubMed  CAS  Google Scholar 

  55. Wilmut I, Schnieke AE, McWhir J, et al. Viable offspring derived from fetal and adult mammalian cells. Nature 1997; 385: 810–3

    Article  PubMed  CAS  Google Scholar 

  56. Lanza RP, Cibelli JB, West MD. Prospects for the use of nuclear transfer in human transplantation. Nat Biotechnol 1999; 17: 1171–4

    Article  PubMed  CAS  Google Scholar 

  57. Humphreys D, Eggan K, Akutsu H, et al. Epigenetic instability in ES cells and cloned mice. Science 2001; 293: 95–7

    Article  Google Scholar 

  58. Vacanti JP, Langer R. Tissue engineering: the design and fabrication of living replacement devices for surgical reconstruction and transplantation. Lancet 1999; 354 Suppl. 1: SI32–4

    PubMed  Google Scholar 

  59. Leor J, Aboulafia-Etzion S, Dar A, et al. Bioengineered cardiac grafts: A new approach to repair the infarcted myocardium?. Circulation 2000; 102: III56–61

    Article  PubMed  CAS  Google Scholar 

  60. Akins RE, Boyce RA, Madonna ML, et al. Cardiac organogenesis in vitro: reestablishment of three-dimensional tissue architecture by dissociated neonatal rat ventricular cells. Tissue Eng 1999; 5: 103–8

    Article  PubMed  CAS  Google Scholar 

  61. Bursac N, Papadaki M, Cohen RJ, et al. Cardiac muscle tissue engineering: toward an in vitro model for electrophysiological studies. Am J Physiol 1999; 277: H433–44

    PubMed  CAS  Google Scholar 

  62. Carrier RL, Papadaki M, Rupnick M, et al. Cardiac tissue engineering: cell seeding, cultivation parameters, and tissue construct characterization. Biotechnol Bioeng 1999; 64: 580–9

    Article  PubMed  CAS  Google Scholar 

  63. Papadaki M, Bursac N, Langer R, et al. Tissue engineering of functional cardiac muscle: molecular, structural, and electrophysiological studies. Am J Physiol Heart Circ Physiol 2001; 280: H168–78

    PubMed  CAS  Google Scholar 

  64. Li RK, Jia ZQ, Weisel RD, et al. Survival and function of bioengineered cardiac grafts. Circulation 1999; 100: II63–9

    PubMed  CAS  Google Scholar 

  65. Bonadio J, Smiley E, Patil P, et al. Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration [see comments]. Nat Med 1999; 5: 753–9

    Article  PubMed  CAS  Google Scholar 

  66. Leor J, Prentice H, Salterelli V, et al. Gene transfer and cell transplant: an experimental approach to repair a ‘broken heart’. Cardiovasc Res 1997; 35: 431–1

    Article  PubMed  CAS  Google Scholar 

  67. Nabel EG. Gene therapy for cardiovascular disease. Circulation 1995; 91: 541–8

    Article  PubMed  CAS  Google Scholar 

  68. Murry CE, Kay MA, Bartosek T, et al. Muscle differentiation during repair of myocardial necrosis in rats via gene transfer with MyoD. J Clin Invest 1996; 98: 2209–17

    Article  PubMed  CAS  Google Scholar 

  69. Prentice H, Kloner RA, Prigozy T, et al. Tissue restricted gene expression assayed by direct DNA injection into cardiac and skeletal muscle. J Mol Cell Cardiol 1994; 26: 1393–401

    Article  PubMed  CAS  Google Scholar 

  70. Guzman RJ, Lemarchand P, Crystal RG, et al. Efficient gene transfer into myocardium by direct injection of adenovirus vectors. Circ Res 1993; 73: 1202–7

    Article  PubMed  CAS  Google Scholar 

  71. Kirshenbaum LA, MacLellan WR, Mazur W, et al. Highly efficient gene transfer into adult ventricular myocytes by recombinant adenovirus. J Clin Invest 1993; 92: 381–7

    Article  PubMed  CAS  Google Scholar 

  72. Quinones MJ, Leor J, Kloner RA, et al. Avoidance of immune response prolongs expression of genes delivered to the adult rat myocardium by replication-defective adenovirus. Circulation 1996; 94: 1394–401

    Article  PubMed  CAS  Google Scholar 

  73. Svensson EC, Marshall DJ, Woodard K, et al. Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors. Circulation 1999; 99: 201–5

    Article  PubMed  CAS  Google Scholar 

  74. Sakoda T, Kasahara N, Hamamori Y, et al. A high-titer lentiviral production system mediates efficient transduction of differentiated cells including beating cardiac myocytes. J Mol Cell Cardiol 1999; 31: 2037–47

    Article  PubMed  CAS  Google Scholar 

  75. Aoki M, Morishita R, Muraishi A, et al. Efficient in vivo gene transfer into the heart in the rat myocardial infarction model using the HVJ (Hemagglutinating Virus of Japan)— liposome method. J Mol Cell Cardiol 1997; 29: 949–59

    Article  PubMed  CAS  Google Scholar 

  76. Leor J, Quinones MJ, Patterson M, et al. Adenovirus-mediated gene transfer into infarcted myocardium: feasibility, timing, and location of expression. J Mol Cell Cardiol 1996; 28: 2057–67

    Article  PubMed  CAS  Google Scholar 

  77. Prentice H, Kloner RA, Li Y, et al. Ischemic/reperfused myocardium can express recombinant protein following direct DNA or retroviral injection. J Mol Cell Cardiol 1996; 28: 133–40

    Article  PubMed  CAS  Google Scholar 

  78. Schwarz ER, Speakman MT, Patterson M, et al. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat — angiogenesis and angioma formation. J Am Coll Cardiol 2000; 35: 1323–30

    Article  PubMed  CAS  Google Scholar 

  79. Lee LY, Patel SR, Hackett NR, et al. Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann Thorac Surg 2000; 69: 14–23; discussion 23-4

    Article  PubMed  CAS  Google Scholar 

  80. Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999; 100: 468–74

    Article  PubMed  CAS  Google Scholar 

  81. Floyd Jr SS, Clemens PR, Ontell MR, et al. Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles. Gene Ther 1998; 5: 19–30

    Article  PubMed  CAS  Google Scholar 

  82. Etzion S, Barbasti IM, Granot Y, et al. Gene-delivery to the infarcted myocardium with ex-vivo modified cardiomyoblasts is superior to direct adenovirusmediated gene transfer. Card Vasc Regen. In press

  83. Lattanzi L, Salvatori G, Coletta M, et al. High efficiency myogenic conversion of human fibroblasts by adenoviral vector-mediated MyoD gene transfer. An alternative strategy for ex vivo gene therapy of primary myopathies. J Clin Invest 1998; 101: 2119–8

    Article  PubMed  CAS  Google Scholar 

  84. Tam SK, Gu W, Nadal-Ginard B. Molecular cardiomyoplasty: potential cardiac gene therapy for chronic heart failure. J Thorac Cardiovasc Surg 1995; 109: 918–23; discussion 923-4

    Article  PubMed  CAS  Google Scholar 

  85. Robinson SW, Cho PW, Levitsky HI, et al. Arterial delivery of genetically labelled skeletal myoblasts to the murine heart: long-term survival and phenotypic modification of implanted myoblasts. Cell Transplant 1996; 5: 77–91

    Article  PubMed  CAS  Google Scholar 

  86. James J, Robbins J. Molecular remodeling of cardiac contractile function. Am J Physiol 1997; 273: H2105–18

    PubMed  CAS  Google Scholar 

  87. Nakao K, Minobe W, Roden R, et al. Myosin heavy chain gene expression in human heart failure. J Clin Invest 1997; 100: 2362–70

    Article  PubMed  CAS  Google Scholar 

  88. Koss KL, Kranias EG. Phospholamban: a prominent regulator of myocardial contractility. Circ Res 1996; 79: 1059–63

    Article  PubMed  CAS  Google Scholar 

  89. Jones WK, Grupp IL, Doetschman T, et al. Ablation of the murine alpha myosin heavy chain gene leads to dosage effects and functional deficits in the heart. J Clin Invest 1996; 98: 1906–7

    Article  PubMed  CAS  Google Scholar 

  90. Luo W, Grupp IL, Harrer J, et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res 1994; 75: 401–9

    Article  PubMed  CAS  Google Scholar 

  91. Hajjar RJ, del Monte F, Matsui T, et al. Prospects for gene therapy for heart failure. Circ Res 2000; 86: 616–21

    Article  PubMed  CAS  Google Scholar 

  92. Hajjar RJ, Schmidt U, Kang JX, et al. Adenoviral gene transfer of phospholamban in isolated rat cardiomyocytes. Rescue effects by concomitant gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase. Circ Res 1997; 81: 145–53

    Article  PubMed  CAS  Google Scholar 

  93. Soonpaa MH, Field LJ. Survey of studies examining mammalian cardiomyocyte DNA synthesis. Circ Res 1998; 83: 15–26

    Article  PubMed  CAS  Google Scholar 

  94. Anversa P, Kajstura J. Ventricular myocytes are not terminally differentiated in the adult mammalian heart. Circ Res 1998; 83: 1–14

    Article  PubMed  CAS  Google Scholar 

  95. Beltrami P, Urbanek K, Kajstura J, et al. Evidence that huamn cardiacmyocytes divide after myocardial infarction. N Engl J Med 2001; 344: 1750–7

    Article  PubMed  CAS  Google Scholar 

  96. MacLellan WR, Schneider MD. Genetic dissection of cardiac growth control pathways. Annu Rev Physiol 2000; 62: 289–319

    Article  PubMed  CAS  Google Scholar 

  97. Schneider MD. Myocardial infarction as a problem of growth control: cell cycle therapy for cardiac myocytes?. J Card Fail 1996; 2: 259–63

    Article  PubMed  CAS  Google Scholar 

  98. Williams RS. Cell cycle control in the terminally differentiated myocyte. A platform for myocardial repair?. Cardiol Clin 1998; 16: 739–54

    Article  PubMed  CAS  Google Scholar 

  99. Li JM, Brooks G. Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system; potential targets for therapy?. Eur Heart J 1999; 20: 406–20

    Article  PubMed  CAS  Google Scholar 

  100. Liu Y, Kitsis RN. Induction of DNA synthesis and apoptosis in cardiac myocytes by E1A oncoprotein. J Cell Biol 1996; 133: 325–4

    Article  PubMed  CAS  Google Scholar 

  101. Kirshenbaum LA, Schneider MD. Adenovirus E1A represses cardiac gene transcription and reactivates DNA synthesis in ventricular myocytes, via alternative pocket protein- and p300-binding domains. J Biol Chem 1995; 270: 7791–4

    Article  PubMed  CAS  Google Scholar 

  102. Kirshenbaum LA, Abdellatif M, Chakraborty S, et al. Human E2F-1 reactivates cell cycle progression in ventricular myocytes and represses cardiac gene transcription. Dev Biol 1996; 179: 402–11

    Article  PubMed  CAS  Google Scholar 

  103. Agah R, Kirshenbaum LA, Abdellatif M, et al. Adenoviral delivery of E2F-1 directs cell cycle reentry and p53- independent apoptosis in postmitotic adult myocardium in vivo. J Clin Invest 1997; 100: 2722–8

    Article  PubMed  CAS  Google Scholar 

  104. Jackson T, Allard MF, Sreenan CM, et al. Transgenic animals as a tool for studying the effect of the c-myc proto-oncogene on cardiac development. Mol Cell Biochem 1991; 104: 15–9

    Article  PubMed  CAS  Google Scholar 

  105. Jackson T, Allard MF, Sreenan CM, et al. The c-myc proto-oncogene regulates cardiac development in transgenic mice. Mol Cell Biol 1990; 10: 3709–16

    PubMed  CAS  Google Scholar 

  106. Soonpaa MH, Koh GY, Pajak L, et al. Cyclin D1 overexpression promotes cardiomyocyte DNA synthesis and multinucleation in transgenic mice. J Clin Invest 1997; 99: 2644–54

    Article  PubMed  CAS  Google Scholar 

  107. Poolman RA, Li JM, Durand B, et al. Altered expression of cell cycle proteins and prolonged duration of cardiac myocyte hyperplasia in p27KIP1 knockout mice. Circ Res 1999; 85: 117–27

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neufeld Cardiac Research Institute, Tel-Aviv University, Sheba Medical Center, Tel-Hashomer, 52621, Israel

    Sharon Etzion &  Jonathan Leor

  2. Cardiac Research Center, Ben-Gurion University, Beer-Sheva, Israel

    Sharon Etzion

  3. Institute for Genetic Medicine, Department of Biochemistry & Molecular Biology, Los Angeles, USA

    Laurence H. Kedes

  4. Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, USA

    Laurence H. Kedes & Robert A. Kloner

  5. The Heart Institute, The Good Samaritan Hospital, Los Angeles, USA

    Robert A. Kloner

Authors
  1. Sharon Etzion
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laurence H. Kedes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert A. Kloner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jonathan Leor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan Leor.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Etzion, S., Kedes, L.H., Kloner, R.A. et al. Myocardial Regeneration. Am J Cordiovosc Drugs 1, 233–244 (2001). https://doi.org/10.2165/00129784-200101040-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00129784-200101040-00002

Keywords

Search

Navigation